{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.4","value":"3.6"},{"groupId":"OG001","spread":"14.6","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"title":"Cycle 2: VAS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.0","value":"4.5"},{"groupId":"OG001","spread":"13.4","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"Cycle 3: VAS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.5","value":"4.6"},{"groupId":"OG001","spread":"18.2","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"title":"Cycle 4: VAS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.1","value":"0.6"},{"groupId":"OG001","spread":"17.0","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"title":"Cycle 5: VAS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.8","value":"-1.3"},{"groupId":"OG001","spread":"23.1","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"Cycle 6: VAS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.1","value":"2.9"},{"groupId":"OG001","spread":"20.1","value":"-0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Cycle 7: VAS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.0","value":"2.8"},{"groupId":"OG001","spread":"19.6","value":"1.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Cycle 8: VAS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.3","value":"-3.3"},{"groupId":"OG001","spread":"23.1","value":"-5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"End of treatment: VAS"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.179","value":"0.026"},{"groupId":"OG001","spread":"0.178","value":"-0.010"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"title":"Cycle 2: Utility Index Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.183","value":"0.041"},{"groupId":"OG001","spread":"0.182","value":"-0.011"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"Cycle 3: Utility Index Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.176","value":"0.051"},{"groupId":"OG001","spread":"0.188","value":"-0.002"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Cycle 4: Utility Index Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.209","value":"0.027"},{"groupId":"OG001","spread":"0.185","value":"-0.035"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"Cycle 5: Utility Index Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.191","value":"0.015"},{"groupId":"OG001","spread":"0.176","value":"-0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Cycle 6: Utility Index Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.182","value":"0.029"},{"groupId":"OG001","spread":"0.153","value":"0.024"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"Cycle 7: Utility Index Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.213","value":"0.008"},{"groupId":"OG001","spread":"0.138","value":"-0.014"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Cycle 8: Utility Index Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.188","value":"-0.048"},{"groupId":"OG001","spread":"0.200","value":"-0.079"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"End of treatment: Utility Index Score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"EQ-5D was a standardized HRQOL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \\& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS scale ranging from 0-100, where 0=worst imaginable health state and 100=best imaginable health state, where higher states indicated better outcomes. Baseline corresponded to last evaluable assessment before treatment administration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Cabazitaxel 25 mg/m\\^2 IV infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic G-CSF as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).","id":"OG000","title":"Cabazitaxel"},{"description":"Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).","id":"OG001","title":"Abiraterone Acetate or Enzalutamide"}],"paramType":"MEAN","populationDescription":"Analysis was performed on Health status population which included participants who received at least one dose of the study drug and with an evaluable EQ-5D-5L at baseline and with at least one post-baseline evaluable EQ-5D-5L. Here 'Number analyzed' signifies participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8 and at End of Treatment (any time up to: 141 weeks)","title":"Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Utility Single Index and Visual Analogue Scale (VAS) Scores at Cycle 2, 3, 4, 5, 6, 7, 8 and End of Treatment","type":"SECONDARY","unitOfMeasure":"score on a scale"}